Adelman ER,Huang HT, Roisman A, Olsson A, Colaprico A, Qin T, Lindsley RC, Bejar R, Salomonis N, Grimes HL, Figueroa ME. Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Cancer Discov. 2019 May 13. pii: CD-18-1474. DOI:10.1158/2159-8290.CD-18-1474. PMID: 31085557
View in: PubMed
Mikkael A. Sekeres, Steven D. Gore, Donald M. Stablein, Nancy DiFronzo, Gregory A. Abel, Amy E. DeZern, Jesse D. Troy, Dana E. Rollison, John W. Thomas, Myron A. Waclawiw, Jane Jijun Liu, Tareq Al Baghdadi, Matthew J. Walter, Rafael Bejar, Edward J. Gorak, Daniel T. Starczynowski, James M. Foran, James R. Cerhan, Lynn C. Moscinski, Rami S. Komrokji, H. Joachim Deeg & Pearlie K. Epling-Burnette (2019) The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes, Leukemia & Lymphoma
View in: 10.1080/10428194.2019.1616186
Park SJ, Bejar. Clonal Hematopoiesis in Aging. Curr Stem Cell Rep. 2018 Sep;4(3):209-219. PMID: 30854305
View in: PubMed
Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica. 2019 Mar 7. PMID: 30846499
View in: PubMed
Tanaka TN, Bejar R. MDS overlap disorders and diagnostic boundaries. Blood. 2019 Mar 7;133(10):1086-1095. PMID: 30670443
View in: PubMed
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Ades L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellstrom-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tuchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. Leukemia. 2019 Jan 11. PMID: 30635634
View in: PubMed
Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21;11(1). PMID: 30583461
View in: PubMed
Bejar R. What biologic factors predict for transformation to AML? Best Pract Res Clin Haematol. 2018 Dec;31(4):341-345. PMID: 30466744
View in: PubMed
Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 Jan 1;37(1):7-11. PMID: 30403571
View in: PubMed
Wang HY, Dell'Aquila ML, Dvanajscak Z, Bejar R, Broome HE, Hsi E, Murray SS, Thorson JA. JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukemia. Br J Haematol. 2018 Aug 21. PMID: 30132795
View in: PubMed
Ozturk K, Dow M, Carlin DE, Bejar R, Carter H. The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. J Mol Biol. 2018 Sep 14;430(18 Pt A):2875-2899. PMID: 29908887
View in: PubMed
Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018 May 24;131(21):2402-2405. PMID: 29661788
View in: PubMed
Sallman DA, Tanaka TN, List A, Bejar R. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):613-620. PMID: 29025689
View in: PubMed
Nazha A, Bejar R. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. Curr Hematol Malig Rep. 2017 Aug 26. PMID: 28844082.
View in: PubMed
Bejar R. Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol. 2017 Mar; 24(2):73-78. PMID: 27875374.
View in: PubMed
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jan; 15(1):60-87. PMID: 28040720.
View in: PubMed
Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2017; 37:480-494. PMID: 28561687.
View in: PubMed
Bejar R, Greenberg PL. The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. J Natl Compr Canc Netw. 2017 Jan; 15(1):131-135. PMID: 28040723.
View in: PubMed
Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leuk Res. 2017 Jan; 52:1-7. PMID: 27855285.
View in: PubMed
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 Aug 19; 16:652. PMID: 27538433; PMCID: PMC4991094.
View in: PubMed
Qiu J, Zhou B, Thol F, Zhou Y, Chen L, Shao C, DeBoever C, Hou J, Li H, Chaturvedi A, Ganser A, Bejar R, Zhang DE, Fu XD, Heuser M. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. RNA. 2016 Oct; 22(10):1535-49. PMID: 27492256.
Song C, Castellanos-Rizaldos E, Bejar R, Ebert BL, Makrigiorgos GM. DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. Clin Chem. 2015 Nov; 61(11):1354-62. PMID: 26432802.
View in: PubMed
Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, Flamholz R, Dabbas B, Yung A, Al-Hafidh J, Balmert E, Vaupel C, El Hader C, McGinniss MJ, Nahas SA, Kines J, Bejar R. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015 Nov 19; 126(21):2355-61. PMID: 26429975; PMCID: PMC4653764.
View in: PubMed
Bejar R. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Curr Hematol Malig Rep. 2015 Sep; 10(3):282-91.
View in: PubMed
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 2; 126(1):9-16.
View in: PubMed
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):261-72.
View in: PubMed
Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest. 2015 Apr 1; 125(4):1665-9.
View in: PubMed
Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20.
View in: PubMed
Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014 Oct 30; 124(18):2793-803.
View in: PubMed
Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12.
View in: PubMed
Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 1; 32(25):2691-8.
View in: PubMed
Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014 Jun; 99(6):956-64.
View in: PubMed
Adema V, Bejar R. What lies beyond del(5q) in myelodysplastic syndrome? Haematologica. 2013 Dec; 98(12):1819-21.
View in: PubMed
Bejar R, Abdel-Wahab O. The importance of subclonal genetic events in MDS. Blood. 2013 Nov 21; 122(22):3550-1.
View in: PubMed
Bejar R, Tiu RV, Sekeres MA, Komrokji RS. Myelodysplastic syndromes. Am Soc Clin Oncol Educ Book. 2013; 256-70.
View in: PubMed
Bejar R. Prognostic models in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2013; 2013:504-10.
View in: PubMed
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82.
View in: PubMed
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30; 364(26):2496-506.
View in: PubMed
Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011 Feb 10; 29(5):504-15.
View in: PubMed
Bejar R, Ebert BL. The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):295-315.
View in: PubMed
Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009 Apr; 29(8):2193-204.
View in: PubMed
Bejar R, Yasuda R, Krugers H, Hood K, Mayford M. Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. J Neurosci. 2002 Jul 1; 22(13):5719-26.
View in: PubMed
Chamberlain MC, Press GA, Bejar RF. Neonatal schizencephaly: comparison of brain imaging. Pediatr Neurol. 1990 Nov-Dec; 6(6):382-7.
View in: PubMed
